Literature DB >> 19318616

Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study.

Veronica Wendy Setiawan1, Kristine R Monroe, Lynne R Wilkens, Laurence N Kolonel, Malcolm C Pike, Brian E Henderson.   

Abstract

Prospective data on ethnic differences in hormone receptor-defined subtypes of breast cancer and their risk factor profiles are scarce. The authors examined the joint distributions of estrogen receptor (ER) and progesterone receptor (PR) status across 5 ethnic groups and the associations of established risk factors with ER/PR status in the Multiethnic Cohort Study (Hawaii and Los Angeles, California). During an average of 10.4 years of follow-up of 84,427 women between 1993-1996 and 2004/2005, 2,543 breast cancer cases with data on ER/PR status were identified: 1,672 estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+); 303 ER+/progesterone receptor-negative (PR-); 77 estrogen receptor-negative (ER-)/PR+; and 491 ER-/PR-. ER/PR status varied significantly across racial/ethnic groups even within the same tumor stage (for localized tumors, P < 0.0001; for advanced tumors, P = 0.01). The highest fraction of ER-/PR- tumors was observed in African Americans (31%), followed by Latinas (25%), Whites (18%), Japanese (14%), and Native Hawaiians (14%). Associations differed between ER+/PR+ and ER-/PR- cases for postmenopausal obesity (P = 0.02), age at menarche (P = 0.05), age at first birth (P = 0.04), and postmenopausal hormone use (P < 0.0001). African Americans are more likely to be diagnosed with ER-/PR- tumors independently of stage at diagnosis, and there are disparate risk factor profiles across the ER/PR subtypes of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318616      PMCID: PMC2727208          DOI: 10.1093/aje/kwp036

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  26 in total

1.  Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women.

Authors:  Thomas A Sellers; Jenny Davis; James R Cerhan; Robert A Vierkant; Janet E Olson; V Shane Pankratz; John D Potter; Aaron R Folsom
Journal:  Am J Epidemiol       Date:  2002-02-01       Impact factor: 4.897

2.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 3.  Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms.

Authors:  K W Singletary; S M Gapstur
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

4.  Interaction of dietary folate intake, alcohol, and risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women.

Authors:  Thomas A Sellers; Robert A Vierkant; James R Cerhan; Susan M Gapstur; Celine M Vachon; Janet E Olson; V Shane Pankratz; Lawrence H Kushi; Aaron R Folsom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-10       Impact factor: 4.254

5.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.

Authors:  L N Kolonel; B E Henderson; J H Hankin; A M Nomura; L R Wilkens; M C Pike; D O Stram; K R Monroe; M E Earle; F S Nagamine
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

6.  Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites.

Authors:  Malcolm C Pike; Laurence N Kolonel; Brian E Henderson; Lynne R Wilkens; Jean H Hankin; Heather Spencer Feigelson; Peggy C Wan; Daniel O Stram; Abraham M Y Nomura
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

7.  Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups.

Authors:  Kenneth C Chu; William F Anderson
Journal:  Breast Cancer Res Treat       Date:  2002-06       Impact factor: 4.872

8.  High prevalence of triple-negative tumors in an urban cancer center.

Authors:  Mary Jo B Lund; Ebonee N Butler; Harvey L Bumpers; Joel Okoli; Monica Rizzo; Nadjo Hatchett; Victoria L Green; Otis W Brawley; Gabriela M Oprea-Ilies; Sheryl G A Gabram
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

9.  Risk factors for breast cancer according to estrogen and progesterone receptor status.

Authors:  Graham A Colditz; Bernard A Rosner; Wendy Y Chen; Michelle D Holmes; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2004-02-04       Impact factor: 13.506

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more
  99 in total

1.  Dietary fat and breast cancer in postmenopausal women according to ethnicity and hormone receptor status: the Multiethnic Cohort Study.

Authors:  Song-Yi Park; Laurence N Kolonel; Brian E Henderson; Lynne R Wilkens
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-13

2.  Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women.

Authors:  Matthew P Banegas; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2012-07-08       Impact factor: 4.872

3.  Disparities in breast cancer characteristics and outcomes by race/ethnicity.

Authors:  Siew Loon Ooi; Maria Elena Martinez; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2010-10-07       Impact factor: 4.872

4.  The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population.

Authors:  Lenora W M Loo; Makana Williams; Brenda Y Hernandez
Journal:  Cancer Epidemiol       Date:  2018-11-30       Impact factor: 2.984

5.  Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics.

Authors:  Roni T Falk; Paige Maas; Catherine Schairer; Nilanjan Chatterjee; Jerome E Mabie; Christopher Cunningham; Saundra S Buys; Claudine Isaacs; Regina G Ziegler
Journal:  Am J Epidemiol       Date:  2014-08-22       Impact factor: 4.897

6.  Estimates of young breast cancer survivors at risk for infertility in the U.S.

Authors:  Katrina F Trivers; Aliza K Fink; Ann H Partridge; Kutluk Oktay; Elizabeth S Ginsburg; Chunyu Li; Lori A Pollack
Journal:  Oncologist       Date:  2014-06-20

Review 7.  The obesity-inflammation-eicosanoid axis in breast cancer.

Authors:  Linda Vona-Davis; David P Rose
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-30       Impact factor: 2.673

Review 8.  Population and target considerations for triple-negative breast cancer clinical trials.

Authors:  Terry Hyslop; Yvonne Michael; Tiffany Avery; Hallgeir Rui
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

9.  Alcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow-up.

Authors:  Kelly A Hirko; Wendy Y Chen; Walter C Willett; Bernard A Rosner; Susan E Hankinson; Andrew H Beck; Rulla M Tamimi; A Heather Eliassen
Journal:  Int J Cancer       Date:  2015-10-05       Impact factor: 7.396

10.  Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.

Authors:  Delisha A Stewart; Jason H Winnike; Susan L McRitchie; Robert F Clark; Wimal W Pathmasiri; Susan J Sumner
Journal:  J Proteome Res       Date:  2016-08-03       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.